EXAM PREP BIOD 351 PHARMACOLOGY
MODULE 1 200 QUESTIONS AND
ANSWERS WITH RATIONALES PORTAGE
LEARNING TOP RATED
BIOD 351 Pharmacology Module 1 Practice Exam
1. Which term best describes the study of how a drug moves through
the body, specifically looking at the processes of absorption,
distribution, metabolism, and excretion?
A) Pharmacodynamics
B) Pharmacokinetics
C) Toxicology
D) Pharmacy
Rationale: Pharmacokinetics is specifically defined as what
the body does to the drug (ADME), whereas pharmacodynamics
is what the drug does to the body.
2. A question regarding significant first-pass metabolism, asking
which route of administration likely yields the lowest
bioavailability.
A) Intravenous (IV) bolus
B) Sublingual
C) Oral (PO)
D) Transdermal
Rationale: Oral medications must pass through the GI tract and
the liver via the portal vein before reaching systemic circulation,
exposing them to extensive "first-pass" metabolism.
3. Which of the following statements is true regarding how
pharmacokinetics changes as a patient ages?
A) Drug absorption is increased due to decreased intestinal blood
flow.
B) Distribution is decreased leading to increased drug effect.
C) Drug metabolism decreases, increasing the duration of
the drug in the body.
D) Excretion is increased due to decreased blood flow to the
kidneys.
, Rationale: In older adults, hepatic blood flow and enzyme activity
often decrease, which slows down drug metabolism and extends
the time the drug remains active in the system.
4. Tablets that are coated with an acid-resistant substance to prevent
dissolution in the stomach and ensure release in the small intestine
are known as:
A) Sustained-release
B) Enteric-coated
C) Immediate-release
D) Extended-release
Rationale: Enteric-coated tablets are designed to protect the
stomach from irritation or protect the drug from stomach acid,
only dissolving once they reach the higher pH of the intestine.
5. When a drug binds to a receptor and produces a physiological
response that mimics the effect of an endogenous substance, it is
acting as a(n):
A) Antagonist
B) Agonist
C) Inverse agonist
D) Competitive inhibitor
Rationale: An agonist is a molecule that binds to a receptor and
activates it to produce a biological response.
6. A scenario where a drug is highly protein-bound (99%) to albumin,
asking for the result if a second drug is administered that competes
for the same binding sites.
A) Increased metabolism of the first drug
B) Decreased volume of distribution
C) Increased free (unbound) concentration of the first
drug
D) Increased renal excretion
Rationale: Displacing a highly bound drug from albumin
increases the free fraction, which is the only pharmacologically
active form of the drug.
7. The time required for the amount of drug in the body to decrease
by 50% is defined as the:
A) Steady state
B) Therapeutic index
C) Half-life (
,)
D) Clearance
Rationale: Half-life is a constant for drugs following first-order
kinetics and determines the dosing interval and the time to reach steady
state.
8. Which organ is primarily responsible for the "Phase I"
functionalization reactions (oxidation, reduction, hydrolysis) of
drug metabolism?
A) Kidneys
B) Liver
C) Lungs
D) Small intestine
Rationale: The liver is the primary site of drug metabolism,
specifically utilizing the Cytochrome P450 enzyme system for
Phase I reactions.
9. Which route of administration provides 100% bioavailability (
) because it completely bypasses the absorption phase?
A) Oral
B) Intravenous
C) Intramuscular
D) Subcutaneous
Rationale: Intravenous administration injects the drug directly into
the bloodstream, meaning the entire dose reaches systemic circulation
immediately.
10. A drug with a high "Therapeutic Index" (TI) is generally
considered:
A) Highly toxic
B) Relatively safe
C) Unstable at room temperature
D) Difficult to absorb
Rationale: The Therapeutic Index is the ratio of the toxic dose
to the effective dose; a higher TI indicates a wider margin of
safety between a beneficial dose and a harmful one.
, 11. Which term describes a drug's ability to produce a maximum
biological effect once it has bound to a receptor?
A) Potency
B) Efficacy
C) Affinity
D) Bioavailability
Rationale: Efficacy refers to the maximum response a drug can
produce, while potency refers to the amount of drug needed to
produce an effect.
12.The "Steady State" concentration of a drug is typically reached
after how many half-lives?
A) 1–2
B) 2–3
C) 4–5
D) 10–12
Rationale: It takes approximately 4 to 5 half-lives for the rate
of drug administration to equal the rate of elimination during
continuous dosing or infusion.
13.Which pharmacokinetic process is most affected by a patient's
glomerular filtration rate (GFR)?
A) Absorption
B) Distribution
C) Metabolism
D) Excretion
Rationale: Excretion via the kidneys depends heavily on the
GFR to filter drugs and their metabolites from the blood into the
urine.
14.A drug that binds to a receptor and prevents the endogenous
ligand from binding, but does not activate the receptor itself, is
a(n):
A) Partial agonist
B) Antagonist
C) Agonist
D) Allosteric activator
Rationale: An antagonist "blocks" the receptor, preventing
other molecules from activating it without triggering a response
itself.
MODULE 1 200 QUESTIONS AND
ANSWERS WITH RATIONALES PORTAGE
LEARNING TOP RATED
BIOD 351 Pharmacology Module 1 Practice Exam
1. Which term best describes the study of how a drug moves through
the body, specifically looking at the processes of absorption,
distribution, metabolism, and excretion?
A) Pharmacodynamics
B) Pharmacokinetics
C) Toxicology
D) Pharmacy
Rationale: Pharmacokinetics is specifically defined as what
the body does to the drug (ADME), whereas pharmacodynamics
is what the drug does to the body.
2. A question regarding significant first-pass metabolism, asking
which route of administration likely yields the lowest
bioavailability.
A) Intravenous (IV) bolus
B) Sublingual
C) Oral (PO)
D) Transdermal
Rationale: Oral medications must pass through the GI tract and
the liver via the portal vein before reaching systemic circulation,
exposing them to extensive "first-pass" metabolism.
3. Which of the following statements is true regarding how
pharmacokinetics changes as a patient ages?
A) Drug absorption is increased due to decreased intestinal blood
flow.
B) Distribution is decreased leading to increased drug effect.
C) Drug metabolism decreases, increasing the duration of
the drug in the body.
D) Excretion is increased due to decreased blood flow to the
kidneys.
, Rationale: In older adults, hepatic blood flow and enzyme activity
often decrease, which slows down drug metabolism and extends
the time the drug remains active in the system.
4. Tablets that are coated with an acid-resistant substance to prevent
dissolution in the stomach and ensure release in the small intestine
are known as:
A) Sustained-release
B) Enteric-coated
C) Immediate-release
D) Extended-release
Rationale: Enteric-coated tablets are designed to protect the
stomach from irritation or protect the drug from stomach acid,
only dissolving once they reach the higher pH of the intestine.
5. When a drug binds to a receptor and produces a physiological
response that mimics the effect of an endogenous substance, it is
acting as a(n):
A) Antagonist
B) Agonist
C) Inverse agonist
D) Competitive inhibitor
Rationale: An agonist is a molecule that binds to a receptor and
activates it to produce a biological response.
6. A scenario where a drug is highly protein-bound (99%) to albumin,
asking for the result if a second drug is administered that competes
for the same binding sites.
A) Increased metabolism of the first drug
B) Decreased volume of distribution
C) Increased free (unbound) concentration of the first
drug
D) Increased renal excretion
Rationale: Displacing a highly bound drug from albumin
increases the free fraction, which is the only pharmacologically
active form of the drug.
7. The time required for the amount of drug in the body to decrease
by 50% is defined as the:
A) Steady state
B) Therapeutic index
C) Half-life (
,)
D) Clearance
Rationale: Half-life is a constant for drugs following first-order
kinetics and determines the dosing interval and the time to reach steady
state.
8. Which organ is primarily responsible for the "Phase I"
functionalization reactions (oxidation, reduction, hydrolysis) of
drug metabolism?
A) Kidneys
B) Liver
C) Lungs
D) Small intestine
Rationale: The liver is the primary site of drug metabolism,
specifically utilizing the Cytochrome P450 enzyme system for
Phase I reactions.
9. Which route of administration provides 100% bioavailability (
) because it completely bypasses the absorption phase?
A) Oral
B) Intravenous
C) Intramuscular
D) Subcutaneous
Rationale: Intravenous administration injects the drug directly into
the bloodstream, meaning the entire dose reaches systemic circulation
immediately.
10. A drug with a high "Therapeutic Index" (TI) is generally
considered:
A) Highly toxic
B) Relatively safe
C) Unstable at room temperature
D) Difficult to absorb
Rationale: The Therapeutic Index is the ratio of the toxic dose
to the effective dose; a higher TI indicates a wider margin of
safety between a beneficial dose and a harmful one.
, 11. Which term describes a drug's ability to produce a maximum
biological effect once it has bound to a receptor?
A) Potency
B) Efficacy
C) Affinity
D) Bioavailability
Rationale: Efficacy refers to the maximum response a drug can
produce, while potency refers to the amount of drug needed to
produce an effect.
12.The "Steady State" concentration of a drug is typically reached
after how many half-lives?
A) 1–2
B) 2–3
C) 4–5
D) 10–12
Rationale: It takes approximately 4 to 5 half-lives for the rate
of drug administration to equal the rate of elimination during
continuous dosing or infusion.
13.Which pharmacokinetic process is most affected by a patient's
glomerular filtration rate (GFR)?
A) Absorption
B) Distribution
C) Metabolism
D) Excretion
Rationale: Excretion via the kidneys depends heavily on the
GFR to filter drugs and their metabolites from the blood into the
urine.
14.A drug that binds to a receptor and prevents the endogenous
ligand from binding, but does not activate the receptor itself, is
a(n):
A) Partial agonist
B) Antagonist
C) Agonist
D) Allosteric activator
Rationale: An antagonist "blocks" the receptor, preventing
other molecules from activating it without triggering a response
itself.
